Galux: Scaling AI-Designed Biologics

Why It Matters

The infusion accelerates commercialization of AI‑generated therapeutics, potentially shortening drug development timelines and lowering costs across the biotech sector.

Key Takeaways

• $29M Series B funding led by Yuanta.
• AI platform merges generative design with high‑throughput screening.
• Collaboration with Boehringer Ingelheim on protein discovery.
• Founded 2020 by Seoul National University professor.
• Aims to scale precision biologic design globally.

Pulse Analysis

The biotech industry is undergoing a rapid transformation as artificial intelligence moves from data analysis to active molecule creation. Generative models can propose novel protein folds, while in silico screening evaluates binding affinity at a scale impossible for traditional wet‑lab methods. This shift promises to compress the discovery phase from years to months, reducing both capital outlay and attrition rates. Investors have responded with heightened enthusiasm, channeling billions into AI‑driven drug platforms that promise higher success probabilities and faster time‑to‑market.

Galux Inc. leverages this momentum by integrating generative AI with high‑throughput experimental pipelines. Founded in 2020 by Professor Chaok Seok and her graduate team at Seoul National University, the startup has already demonstrated the ability to design both therapeutic proteins and monoclonal antibodies in silico before confirming activity in the lab. The recent $29 million Series B round, led by Yuanta, not only validates the commercial appeal of its platform but also funds expansion of its screening infrastructure and deeper collaborations, such as the newly announced partnership with Boehringer Ingelheim on AI‑guided protein discovery.

If Galux can deliver scalable, high‑precision biologics, it could reshape the economics of antibody and protein therapeutics, making personalized medicines more attainable for smaller markets. Competitors such as Insilico Medicine and Exscientia are pursuing similar AI‑centric pipelines, intensifying the race for first‑to‑market breakthroughs. However, regulatory pathways for AI‑generated biologics remain nascent, and validation through clinical trials will be the ultimate test. Successful execution would not only boost Galux’s valuation but also signal a broader industry shift toward data‑driven drug design.